TCT Announces Late-Breaking Clinical Trials and Science Sessions

Aug. 27, 2025 – The Cardiovascular Research Foundation (CRF) has announced the late-breaking clinical trials and science that will be presented at TCT 2025, the annual scientific symposium of CRF that will take place Oct. 25–28, in San Francisco.

For more than 30 years, TCT has served as a cornerstone for advancing cardiovascular care, showcasing transformative research and fostering collaboration across disciplines. Each year, the symposium delivers pivotal data that shapes clinical practice and enhances outcomes for patients with heart and vascular disease.

Late-breaking clinical trials and science are among the most anticipated sessions, offering first looks at novel therapies, devices, and techniques. This year, 28 cutting-edge studies will be presented, focusing on the safety and efficacy of minimally invasive procedures, emerging pharmaceuticals, and breakthrough technologies aimed at preventing and treating cardiovascular conditions.

These high-impact findings will be featured in the main program and spotlighted during dedicated press briefings.

Oct. 26, 2025

One-Year Results of the SELUTION DeNovo Trial Comparing a Strategy of PCI with a Sirolimus-eluting Balloon and Provisional Stenting Versus Systematic DES Implantation to Treat DeNovo Coronary Lesions —Christian M. Spaulding
Sirolimus-Eluting Balloon Versus Repeat Drug-Eluting Stenting or Balloon Angioplasty for In-stent Restenosis — Donald Cutlip
Randomized Comparison of Intravascular Lithotripsy vs. Cutting Balloon Treatment in Calcified Coronary Artery Disease – The Short-CUT Trial — Suzanne J. Baron
A Randomized, Multicenter, Non-Inferiority Comparison of Intravascular Lithotripsy and Super-High-Pressure Non-Compliant Balloons for Treatment of Calcified and Refractory Coronary Lesions - The VICTORY Trial
Randomized Controlled Trial of Mechanical Thrombectomy with Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Results from STORM-PE — Robert A. Lookstein
Three-Year Outcomes of the LIFE-BTK Randomized Controlled Trial Evaluating the Esprit BTK Drug-Eluting Resorbable Scaffold for Treatment of Infrapopliteal Lesions — Sahil A. Parikh
Short-Term Anticoagulation Versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure —Josep Rodés-Cabau
Evaluating Real-World Outcomes of the EVOQUE Valve in Early Commercial Experience from the STS/ACC TVT Registry — Raj Makkar
Lessons Learned from 800+ Patients Treated with Tricuspid TEER: Update from the TRILUMINATE Pivotal Trial — Jonathan G. Schwartz

Oct. 27, 2025

Defining the Prevalence of Valvular Heart Disease in Older Americans: The PREVUE-VALVE Study — David J. Cohen
Long-Term Follow-up of the PARTNER 3 Low-Risk Randomized Trial: Seven-Year Clinical and Echocardiographic Outcomes — Michael J. Mack
Tendyne Transcatheter Mitral Valve System in Patients with Severe Mitral Annular Calcification: One-year Outcomes from the SUMMIT Severe MAC Cohort — Paul Sorajja
Percutaneous Transseptal Transcatheter Mitral Valve Replacement using a Dedicated Balloon Expandable Valve: 1 Year Outcomes from the ENCIRCLE Trial using the SAPIEN M3 — David Daniels
Long Term Clinical Outcomes in Patients Treated with the Bioadaptor Compared with a Contemporary Drug Eluting Stent: The INFINITY-SWEDEHEART Randomized Trial — David Erlinge
Comparison of Drug-Coated Versus Conventional Balloons for Treatment of Side Branches of Bifurcation Lesions: The OCVC-BIF Study — Takayuki Ishihara
Sirolimus-Eluting Iron Bioresorbable Scaffold in Coronary Artery Disease: Two-Year Results of IRONMAN-II Randomized Controlled Trial — Lei Song
Drug-Coated Balloon Angioplasty with Rescue Stenting Versus Intended Stenting for the Treatment of DeNovo Coronary Artery Lesions: 3-Year Clinical Outcomes of the REC-CAGEFREE I Trial — Chao Gao
Percutaneous Coronary Angioplasty Versus Coronary Artery Bypass Grafting in the Treatment of Unprotected Left Main Stenosis: 10-year Mortality Outcomes from the Randomized NOBLE Trial — Evald H. Christiansen

Oct. 28, 2025

Percutaneous Coronary Intervention of Native Coronary Artery versus Saphenous Vein Graft in Patients with Prior Coronary Artery Bypass Graft Surgery (PROCTOR): A Multicenter, Open-label, Randomized Trial — Ruben de Winter
Effects of Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator as an Ajunct to Primary PCI in Patients with STEMI and Large Thrombus Burden: A Randomized, Double-Blind, Placebo-Controlled Trial — Shamir R. Mehta
Immediate Instantaneous Wave-Free Ratio Guided Versus Deferred Cardiac Magnetic Resonance Imaging Guided Revascularization of Non-Culprit Lesions in Patients with Acute ST-Elevation Myocardial Infarction: A Randomized Superiority Trial — Robin Nijveldt
Stratified Treatment of Myocardial Infarction with Non-Obstructive Coronary Arteries: The PROMISE Trial — Rocco Antonio Montone
Supraflex Cruz versus Xience in Patients with Diabetes and Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: Results from the TUXEDO-2 Randomized Trial — Upendra Kaul
iFR Versus Angiography-Guided CABG: 3-Year Results of the iCABG Randomized Trial —Rasa Ordiene
Randomized Comparison of the Supraflex CruzTM vs. SYNERGYTM Drug-Eluting Stents: The Multivessel TALENT Randomized Trial — Patrick W. Serruys
A Prospective, Randomized Clinical Trial of Hemodynamic Support with a Novel Developed pVAD Versus IABP in Patients Undergoing High-Risk Percutaneous Coronary Intervention — Rui Wang
AI-Enabled ECG Interpretation in STEMI: Findings from a Multicenter U.S. Registry — Timothy D. Henry
The Effectiveness and Safety of a Planned Investment Procedure in High-Risk Chronic Total Occlusions - The INVEST CTO Single Arm Study — Anja Oksnes